Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth (CSE: VREO, OTCQX: VREOF) engaged Independent Trading Group (ITG) to provide market-making services under Canadian Securities Exchange policies and securities laws.
ITG will trade Vireo subordinate voting shares on the CSE and other venues to maintain a reasonable market and support liquidity objectives, starting around July 7, 2026.
Vireo Growth (CSE: VREO, OTCQX: VREOF; Symbol: VREOD) agreed to acquire, with joint venture Vive Penn, all membership interests of FarmX d/b/a PhytoNatural, which holds a non-operational Pennsylvania retail permit. The deal, valued at about $20 million, supports expansion into Vireo’s 11th state.
Consideration includes $8 million cash at closing from Vive and $12 million in about 645,161 Vireo subordinate voting shares issued two years after closing. The permit could allow up to six medical dispensaries, subject to regulatory approvals and customary closing conditions.
Vireo Growth (CSE:VREO, OTCQX:VREOD) closed its previously announced acquisition of an indirect 49% equity interest in HA-MD, LLC, owner of two Maryland dispensaries. Total consideration is $1.55 million, paid via cash, an interest-bearing promissory note, and issuance of 37,035 shares at a deemed price of $20.25.
Vireo Growth (OTCQX:VREOF) signed a definitive arrangement agreement to acquire all C21 Investments shares in an all-stock deal. Each C21 share will receive 0.023052 Vireo subordinate voting share. The combination is expected to expand Vireo’s Nevada footprint to about 15 dispensaries and 158,000 sq. ft. of cultivation and manufacturing capacity.
The plan of arrangement requires C21 shareholder, court and regulatory approvals. Both boards unanimously approved the deal, supported by a C21 special committee, a Needham fairness opinion, voting support agreements and a US$3 million termination fee payable by C21 in specified circumstances.
Vireo Growth (CSE: VREO, OTCQX: VREOD) appointed BDO USA as its new independent registered public accounting firm, effective immediately, following the June 5 dismissal of Davidson & Company. The Board and Audit Committee approved both decisions, and the company reports no disagreements or reportable events with Davidson. A Form 8-K will provide further details on EDGAR and SEDAR+.
Vireo Growth (OTCQX: VREOF) closed its acquisition of Agribusiness Holdings, including Bridgewell Agribusiness, a supplier of organic and non-GMO food and agricultural products. The Bridgewell deal uses a base purchase price of US$40M, with an estimated closing price of US$13.66M, partly via unsecured, subordinated convertible notes that may convert into about 22.0M shares at US$0.62 each.
Vireo also agreed to acquire a Nevada dispensary from M3 Wellness for $500K and a 49% equity interest in Maryland dispensaries from HA-MD for $1.55M, both with mixed cash and share consideration and subject to closing conditions.
Vireo Growth (CSE:VREO, OTCQX:VREOF) approved a 30-for-1 consolidation of its subordinate, multiple and super voting share classes, effective at market open on June 5, 2026.
Subordinate shares will decline from 1,455,017,319 to about 48,500,577, and multiple voting shares from 232,490 to about 7,749, with ownership percentages largely unchanged aside from rounding.
Vireo Growth (OTCQX:VREOF) completed the acquisition of its 389,000 square foot cannabis cultivation and production facility at 256 County Route 117 in Perth, New York, previously leased from Innovative Industrial Properties.
The US$88.5 million purchase was funded by a US$49 million seller-financed note at 15% interest, maturing May 25, 2027 with two one-year extension options, and a US$41.0 million loan from Chicago Atlantic secured by a second mortgage.
Vireo Growth (CSE: VREO, OTCQX: VREOF) plans to acquire all membership interests of Bridgewell Agribusiness, a privately held supplier of organic and non-GMO food and agricultural products. The base purchase price is US$40 million, including about US$30 million of assumed debt, with an estimated closing purchase price of US$10.26 million.
Vireo will issue an unsecured, subordinated convertible note equal to the closing purchase price, expected to convert after two years into about 16.55 million subordinate voting shares at a deemed price near US$0.62, subject to adjustments, regulatory approvals, and definitive agreements. The shares will be restricted and subject to resale limits in the United States and Canada.
Vireo Growth (OTCQX: VREOF) reported Q1 2026 GAAP revenue of $106.2 million, up 333.5% year-over-year, with GAAP gross profit of $59.3 million and adjusted EBITDA of $32.7 million (30.8% margin). Pro forma revenue was $210.2 million and pro forma cannabis adjusted EBITDA margin was 21.8%.
The company closed the Schwazze acquisition and activated the PharmaCann management agreement, then completed the Eaze and Hawthorne deals after quarter-end. It also agreed to acquire FLUENT and form a 50/50 California retail joint venture with Glass House. Cash stood at $137.8 million versus current liabilities of $82.0 million.